SEC Comment Letter 0000000000-23-012333 to InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc.
Date: Nov. 10, 2023 · CIK: 0001728328 · Accession: 0000000000-23-012333
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275410
Letter
United States securities and exchange commission logo November 9, 2023 Eric A. Adams President and Chief Executive Officer InMed Pharmaceuticals Inc. Suite 310 – 815 West Hastings Street Vancouver, British Columbia V6C 1B4 Canada Re:InMed Pharmaceuticals Inc. Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275410 Dear Eric A. Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Fenske
Show Raw Text
United States securities and exchange commission logo
November 9, 2023
Eric A. Adams
President and Chief Executive Officer
InMed Pharmaceuticals Inc.
Suite 310 – 815 West Hastings Street
Vancouver, British Columbia V6C 1B4
Canada
Re:InMed Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed November 8, 2023
File No. 333-275410
Dear Eric A. Adams:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian Fenske